CRVS

Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)

About Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Details

Daily high

$3.61

Daily low

$3.47

Price at open

$3.59

52 Week High

$10.00

52 Week Low

$1.75

Market cap

279.9M

Dividend yield

0.00%

Volume

547,317

Avg. volume

1.5M

P/E ratio

-3.69

Corvus Pharmaceuticals, Inc. - Common Stock News